Objectives: Clostridium difficile infection (CDI) is still a major clinical challenge. Previous studies have demonstrated multiple distinct C. difficile strains in the faeces of patients with CDI; yet whether true mixed CDI occurs in vivo is unclear. In this study we evaluated whether two distinct C. difficile strains could co-germinate and co-proliferate in an in vitro human gut model.
Introduction
Clostridium difficile infection (CDI) is the leading cause of infectious diarrhoea in healthcare institutions worldwide. US healthcare costs attributable to CDI were recently estimated as $500 million. 1 Understanding how infection occurs and is spread is crucial to optimizing interventions. Recurrent CDI may be due to either relapses attributable to the original infecting strain or re-infections with a different strain. 2 -4 Notably, Eyre et al. 4 recently demonstrated, using multilocus sequence typing, the presence of mixed C. difficile strains in 7% of CDIs. Despite such observations, it is unclear whether multiple C. difficile strains are capable of truly coinfecting a patient, i.e. both strains proliferate and produce toxins, or if the perturbed colonic environment is only able to support growth and toxin production by a single strain.
We have previously used a triple-stage chemostat human gut model to investigate the induction of CDI and also the efficacies of therapies. 5 -7 Results from the gut model correlate well with clinical observations. 5 -7 We have now examined the effects of antibiotic exposure on two distinct C. difficile strains and the gut microflora in a mixed-infection gut model.
Materials and methods

C. difficile strains
Two C. difficile ribotype 001 strains were studied; both isolated from cytotoxin-positive faeces of patients with CDI at Leeds General Infirmary (Leeds, UK). The clindamycin-resistant (MIC ≥ 256 mg/L) metronidazolesusceptible (MIC ≤ 0.25 mg/L) C. difficile (CD-CR, strain P62) isolate was erm(B) positive. 8 The mechanism of reduced susceptibility to metronidazole in the other C. difficile isolate (CD-RM, strain 11/11, MIC 8 mg/L) is undetermined; 9 this strain was clindamycin susceptible (MIC 2 mg/L). PCR ribotyping was performed as described previously. 
Gut model
The gut model was previously validated against physicochemical/ microbiological measurements from the intestinal contents of victims of sudden death 11 and provides a reproducible and gut-reflective environment for studying C. difficile. The gut model comprises three pH-maintained vessels (pH 5.5+0.1-6.8+0.1) inoculated with pooled C. difficile-negative faeces. 12 Enumeration of gut microflora and C. difficile cytotoxin Gut bacterial populations and C. difficile were enumerated as described previously. 12 The C. difficile isolates were distinguished by culture on agar that contained antibiotics: CD-CR was isolated on Brazier's CCEYL 12 agar containing 8 mg/L clindamycin and CD-RM was isolated on Brazier's CCEYL agar containing 1 mg/L metronidazole. C. difficile spore counts were determined using alcohol-shock. 12 Total C. difficile viable counts and spore counts were also determined on CCEYL agar. Total C. difficile cytotoxin titres were monitored by Vero cell cytotoxicity assay and expressed as log 10 relative units (RU).
12 C. difficile total viable counts, spore counts and cytotoxin titres were assayed in all gut model vessels; gut microflora populations were measured in vessels 2 and 3.
Experimental design
Following inoculation of the gut model with faecal emulsion (day 0) no further interventions were made for 13 days (period A). C. difficile spores (10 8 cfu per strain) were prepared as described previously 13 and inoculated into vessel 1 on day 13 (period B). After 7 days (day 20) a further single inoculum of C. difficile spores was instilled into vessel 1 followed by 150 mg/L ceftriaxone once-daily for 7 days (period C). Ceftriaxone was instilled to reflect the concentration observed in faeces of patients and volunteers.
14 Following cessation of cephalosporin instillation, gut bacterial populations and C. difficile cytotoxin titres were monitored for a further 14 days (period D).
Antimicrobial bioassay
Gut model samples were stored at 2208C before ceftriaxone bioassay. Mueller-Hinton agar (100 mL volumes) was autoclaved, cooled (508C), seeded with 10 6 cfu E. coli ATCC 25922 and poured into bioassay dishes. Twenty microlitre aliquots of filter-sterilized (0.22 mm) culture or calibrator (1-1024 mg/L) were assigned randomly in duplicate to wells (9 mm). Plates were incubated overnight (378C) and zone diameters were measured. Coefficient of variation values were 15% and R 2 values for calibration lines were .0.98. The limit of detection was 1 mg/L.
Results
Specificity of CCEYL breakpoint agar
Preliminary experiments demonstrated that CD-CR and CD-RM were unrecoverable on metronidazole-and clindamycincontaining agar, respectively. Multilocus variable tandem-repeat analysis (MLVA) 10 was performed on C. difficile recovered on each antibiotic selective agar; this confirmed the correct MLVA profile for each strain.
Response of C. difficile and gut microflora to ceftriaxone
Vessel 3 gut model data are shown graphically in this report. Total viable bacterial counts were predominantly stable before ceftriaxone instillation. Both C. difficile populations remained quiescent before ceftriaxone instillation and exited gut model vessels at similar rates. Cultivable gut microfloras at this time were dominated by obligate anaerobes; particularly Bifidobacterium spp. and Bacteroides fragilis group, whereas Clostridium spp. and facultative anaerobes were less numerous (Figure 1 ). Ceftriaxone instillation elicited declines in lactose-fermenting Enterobacteriaceae (2 log 10 cfu/mL) and Lactobacillus spp. (1 log 10 cfu/mL), yet Enterococcus spp. increased (.3 log 10 cfu/mL). The B. fragilis group were largely unaffected by ceftriaxone, but Bifidobacterium spp. declined markedly (Figure 1) . The spore populations of both C. difficile strains germinated during ceftriaxone dosing (total viable counts increased over spore counts) 3 and 4 days after commencement for CD-CR and CD-RM strains, respectively (Figure 2 ). C. difficile germination and proliferation were similar in vessel 2, but were absent in vessel 1. Maximal CD-RM and CD-CR total viable counts were similar in vessels 2 and 3. C. difficile cytotoxin was detected on the last day of ceftriaxone dosing in vessels 2 and 3, but was absent in vessel 1. Ceftriaxone was detectable in vessel 1 (peak concentration 150 mg/L) and concentrations declined rapidly and fell below the limits of detection on day 29 (2 days after ceftriaxone cessation).
Bacterial ecology after ceftriaxone dosing
Lactose-fermenting Enterobacteriaceae and Bifidobacterium spp. normalized midway through period D; yet Enterococcus spp. remained elevated. CD-RM and CD-CR total viable counts declined in vessel 3 during the first 4 days of period D; CD-CR strain counts declined at a greater rate than those of CD-RM, and re-converged with CD-CR spore counts. CD-RM viable counts did not decline in vessel 2 after ceftriaxone cessation, in contrast to CD-CR total viable counts, which declined sharply by 2 log 10 cfu/mL. C. difficile germination was delayed in vessel 1 until days 31 (CD-CR) and 33 (CD-RM), following which increased total viable counts were observed in vessel 3. By the end of the experiment, indigenous microfloras normalized to steady-state levels, except Enterococcus spp., which remained elevated. C. difficile total viable counts were 1 log 10 cfu/mL higher than spore counts and cytotoxin was undetectable.
Discussion
Cephalosporin administration is a documented risk factor for CDI. 15 Ceftriaxone dosing in the present study aimed to simulate the expected in vivo concentrations. Pletz et al.
14 demonstrated 152 mg/kg and 258 mg/kg ceftriaxone in faeces from patients 4 and 8 days after commencing therapy, respectively; these levels reflect the ceftriaxone concentrations observed in gut model vessel 1 (assuming mg/kg mg/L). We were unable to detect active drug in gut model vessels 2 or 3. Similarly low levels of detectable ceftriaxone in vessels 2 and 3 of the gut model have been noted previously. 16 Inactivation of b-lactams in faeces may occur through enzymatic hydrolysis or adsorption to macromolecules. 17, 18 Absence of detectable ceftriaxone in the distal gut model vessels was probably a result of one or both of these mechanisms. Ceftriaxone elicited a minimally deleterious effect against the gut microflora; Bifidobacterium spp. and to a lesser extent lactose-fermenting Enterobacteriaceae were most inhibited. Proliferation of CD-CR and CD-RM strains occurred similarly, within 1 day during ceftriaxone dosing. This suggested that both strains responded to similar germinant(s)/stimuli in the model and that there was no obvious fitness cost associated with each resistance phenotype during germination/proliferation phases. However, differences in growth were observed as C. difficile strains entered stationary/decline phases; total vegetative CD-CR declined more rapidly than CD-RM and re-converged with spore counts. Total viable counts of both strains then increased, while the indigenous gut microflora remained perturbed. We observed similar C. difficile PCR ribotype 027 biphasic growth previously. 12 The second cycle of proliferation may have been a result of delayed spore germination (after washout of bioactive ceftriaxone) in gut model vessel 1 and transfer of germinated spores/vegetative cells downstream. Maximal cytotoxin expression observed in this study was 2 -3 log 10 RU lower than for other epidemic C. difficile we have studied. The concentrations of C. difficile toxins released in vitro and in vivo are known to vary 7, 19 and in the present study it is unlikely that the lower cytotoxin production was a consequence of the resistance phenotype of either strain. Although we detected cytotoxin production in this experiment, we could of course not demonstrate if one or both strains were responsible. However, given that spores of both C. difficile isolates germinated and proliferated in a similar way, it is likely that both strains contributed to the measured titre. The significance of the smaller decline phase of CD-RM is unclear; this may be an intrinsic trait of this C. difficile strain or somehow connected to the resistance phenotype. Further gut model studies are required to assess the profile of growth/ decline phases.
This study clearly demonstrated that two distinct C. difficile strains proliferated concurrently in a complex in vitro model following antimicrobial stimulation. These data supplement epidemiological studies performed in patients with CDI, which identified multiple C. difficile PCR ribotypes in the faeces of these patients 2 -4 and the hypothesis that in vivo coinfection by more than one C. difficile strain is possible. This body of evidence indicates that C. difficile epidemiological studies should ideally examine multiple colony picks and use highly discriminatory fingerprinting techniques, such as MLVA or whole genome sequencing, 10, 20 to ensure that potentially misleading data are not reported. Whether some C. difficile strains, for example epidemic ribotypes such as 027 and 078, actually outcompete others in the gut is unknown, but warrants further study. The phenomenon of mixed infection is important, especially as hospitalized patients in particular may be exposed to multiple C. difficile strains. Enterocccus spp.
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